European Association of Urology Guidelines for Clear Cell Renal Cancers That Are Resistant to Vascular Endothelial Growth Factor Receptor–Targeted Therapy

Thomas Powles; Michael Staehler; Börje Ljungberg; Karim Bensalah; Steven E. Canfield; Saeed Dabestani; Rachel H. Giles; Fabian Hofmann; Milan Hora; Markus A. Kuczyk; Thomas Lam; Lorenzo Marconi; Axel S. Merseburger; Alessandro Volpe; Axel Bex

doi:10.1016/j.eururo.2016.06.009

European Association of Urology Guidelines for Clear Cell Renal Cancers That Are Resistant to Vascular Endothelial Growth Factor Receptor–Targeted Therapy

Thomas Powles^*, Michael Staehler, Börje Ljungberg, Karim Bensalah, Steven E. Canfield, Saeed Dabestani, Rachel H. Giles, Fabian Hofmann, Milan Hora, Markus A. Kuczyk, Thomas Lam, Lorenzo Marconi, Axel S. Merseburger, Alessandro Volpe, Axel Bex

^*Corresponding author for this work

Department of Urology

39 Citations (Scopus)

Abstract

The European Association of Urology renal cancer guidelines panel recommends nivolumab and cabozantinib over the previous standard of care in patients who have failed one or more lines of vascular endothelial growth factor–targeted therapy. New data have recently become available showing a survival benefit for cabozantinib.

Original language	English
Journal	European Urology
Volume	70
Issue number	5
Pages (from-to)	705-706
Number of pages	2
ISSN	0302-2838
DOIs	https://doi.org/10.1016/j.eururo.2016.06.009
Publication status	Published - 11.2016

Funding

Conflicts of interest: T. Powles is a company consultant for Novartis, Pfizer, GSK; has received company speaker honoraria from Novartis, Pfizer, GSK, Genentech; performed trial participation for GSK, Pfizer, BMS, Genentech, Genetech; and received grants/research support from GSK, Pfizer, and Novartis. A. Bex has received company speaker honoraria from Pfizer; performed trial participation for Pfizer Europe; participated on advisory boards for GSK and Novartis; is a company consultant for Pfizer and Novartis; and received grants/research support from Pfizer. M. Staehler is a company consultant for Pfizer, Novartis, GSK, Roche, Astellas, Bayer; has received company speaker honoraria from Pfizer, Novartis, GSK, Roche, Astellas, Bayer, Aveo; has performed trial participation for Pfizer, Novartis, GSK, Roche, Bayer, Aveo, Wilex, Immatics; has received fellowships and travel grants from Pfizer, Novartis, GSK, Roche, Bayer; has received grants/research support from Pfizer, Novartis, GSK, Roche, Bayer, and Aveo. B. Ljungberg has received company speaker honoraria from GlaxoSmithKline, Roche, Pfizer, Novartis; performed trial participation for GlaxoSmithKline, Medivation, Pfizer, Janssen R&D, Inc.; and been on advisory boards for Pfizer and GSK. K. Bensalah has received grants/research support from Pfizer and honoraria or consultation fees from Intuitive Surgical. S. Canfield has received company speaker honoraria from Amgen, Genomic Health, Algeta, and Bayer. M. Hora has received company speaker honoraria from Covidien, Olympus, Janssen, Astellas; performed trial participation for Janssen; and received grants/research support from Ipsen. M.A. Kuczyk is a stock shareholder of Bayer Healthcare, Astellas, Storz, Pfizer, Wyeth, Novartis; is a company consultant for Karl Storz, Coloplast, AstraZeneca, Astellas, Storz, Hexal AG; has received company speaker honoraria from Pfizer, Astellas, Bayer, GSK, Pierre Fabre, Janssen Cilag, Hexal; performed trial participation for the Protect Study, Millenium Study C21004, Millenium Study C21005, Astellas, Ipsen, Janssen; and received grants/research support from Wyeth and Pfizer. T. Lam is a company consultant for and has received company speaker honoraria from Pfizer, GSK, Astellas, and Ipsen. A. Merseburger is a company consultant for Ipsen Pharma, Bayer, Astellas, Janssen Cilag, Novartis, and Pfizer; has received company speaker honoraria from Ipsen Pharma, Wyeth, Astellas, Novartis, Pfizer, SEP; performed trial participation for AstraZeneca, Bayer, Pfizer, TEVA, Novartis, Astellas; received grants/research support from Wyeth; and participated in a company-sponsored speakers bureau for TEVA, Janssen, Pfizer, Astellas, Ferring, and Novartis. S. Dabestani, R.H. Giles, F. Hofmann, L. Marconi, and A. Volpe have nothing to disclose.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Research Areas and Centers

Research Area: Luebeck Integrated Oncology Network (LION)

Access to Document

10.1016/j.eururo.2016.06.009

Cite this

Powles, T., Staehler, M., Ljungberg, B., Bensalah, K., Canfield, S. E., Dabestani, S., Giles, R. H., Hofmann, F., Hora, M., Kuczyk, M. A., Lam, T., Marconi, L., Merseburger, A. S., Volpe, A., & Bex, A. (2016). European Association of Urology Guidelines for Clear Cell Renal Cancers That Are Resistant to Vascular Endothelial Growth Factor Receptor–Targeted Therapy. European Urology, 70(5), 705-706. https://doi.org/10.1016/j.eururo.2016.06.009

@article{1146a01ce9094e488867d49ad0a239d4,

title = "European Association of Urology Guidelines for Clear Cell Renal Cancers That Are Resistant to Vascular Endothelial Growth Factor Receptor–Targeted Therapy",

abstract = "The European Association of Urology renal cancer guidelines panel recommends nivolumab and cabozantinib over the previous standard of care in patients who have failed one or more lines of vascular endothelial growth factor–targeted therapy. New data have recently become available showing a survival benefit for cabozantinib.",

author = "Thomas Powles and Michael Staehler and B{\"o}rje Ljungberg and Karim Bensalah and Canfield, \{Steven E.\} and Saeed Dabestani and Giles, \{Rachel H.\} and Fabian Hofmann and Milan Hora and Kuczyk, \{Markus A.\} and Thomas Lam and Lorenzo Marconi and Merseburger, \{Axel S.\} and Alessandro Volpe and Axel Bex",

note = "Funding Information: Conflicts of interest: T. Powles is a company consultant for Novartis, Pfizer, GSK; has received company speaker honoraria from Novartis, Pfizer, GSK, Genentech; performed trial participation for GSK, Pfizer, BMS, Genentech, Genetech; and received grants/research support from GSK, Pfizer, and Novartis. A. Bex has received company speaker honoraria from Pfizer; performed trial participation for Pfizer Europe; participated on advisory boards for GSK and Novartis; is a company consultant for Pfizer and Novartis; and received grants/research support from Pfizer. M. Staehler is a company consultant for Pfizer, Novartis, GSK, Roche, Astellas, Bayer; has received company speaker honoraria from Pfizer, Novartis, GSK, Roche, Astellas, Bayer, Aveo; has performed trial participation for Pfizer, Novartis, GSK, Roche, Bayer, Aveo, Wilex, Immatics; has received fellowships and travel grants from Pfizer, Novartis, GSK, Roche, Bayer; has received grants/research support from Pfizer, Novartis, GSK, Roche, Bayer, and Aveo. B. Ljungberg has received company speaker honoraria from GlaxoSmithKline, Roche, Pfizer, Novartis; performed trial participation for GlaxoSmithKline, Medivation, Pfizer, Janssen R\&D, Inc.; and been on advisory boards for Pfizer and GSK. K. Bensalah has received grants/research support from Pfizer and honoraria or consultation fees from Intuitive Surgical. S. Canfield has received company speaker honoraria from Amgen, Genomic Health, Algeta, and Bayer. M. Hora has received company speaker honoraria from Covidien, Olympus, Janssen, Astellas; performed trial participation for Janssen; and received grants/research support from Ipsen. M.A. Kuczyk is a stock shareholder of Bayer Healthcare, Astellas, Storz, Pfizer, Wyeth, Novartis; is a company consultant for Karl Storz, Coloplast, AstraZeneca, Astellas, Storz, Hexal AG; has received company speaker honoraria from Pfizer, Astellas, Bayer, GSK, Pierre Fabre, Janssen Cilag, Hexal; performed trial participation for the Protect Study, Millenium Study C21004, Millenium Study C21005, Astellas, Ipsen, Janssen; and received grants/research support from Wyeth and Pfizer. T. Lam is a company consultant for and has received company speaker honoraria from Pfizer, GSK, Astellas, and Ipsen. A. Merseburger is a company consultant for Ipsen Pharma, Bayer, Astellas, Janssen Cilag, Novartis, and Pfizer; has received company speaker honoraria from Ipsen Pharma, Wyeth, Astellas, Novartis, Pfizer, SEP; performed trial participation for AstraZeneca, Bayer, Pfizer, TEVA, Novartis, Astellas; received grants/research support from Wyeth; and participated in a company-sponsored speakers bureau for TEVA, Janssen, Pfizer, Astellas, Ferring, and Novartis. S. Dabestani, R.H. Giles, F. Hofmann, L. Marconi, and A. Volpe have nothing to disclose. Publisher Copyright: {\textcopyright} 2016 European Association of Urology Copyright: Copyright 2017 Elsevier B.V., All rights reserved.",

year = "2016",

month = nov,

doi = "10.1016/j.eururo.2016.06.009",

language = "English",

volume = "70",

pages = "705--706",

journal = "European Urology",

issn = "0302-2838",

publisher = "Elsevier B.V.",

number = "5",

}

Powles, T, Staehler, M, Ljungberg, B, Bensalah, K, Canfield, SE, Dabestani, S, Giles, RH, Hofmann, F, Hora, M, Kuczyk, MA, Lam, T, Marconi, L, Merseburger, AS, Volpe, A & Bex, A 2016, 'European Association of Urology Guidelines for Clear Cell Renal Cancers That Are Resistant to Vascular Endothelial Growth Factor Receptor–Targeted Therapy', European Urology, vol. 70, no. 5, pp. 705-706. https://doi.org/10.1016/j.eururo.2016.06.009

TY - JOUR

T1 - European Association of Urology Guidelines for Clear Cell Renal Cancers That Are Resistant to Vascular Endothelial Growth Factor Receptor–Targeted Therapy

AU - Powles, Thomas

AU - Staehler, Michael

AU - Ljungberg, Börje

AU - Bensalah, Karim

AU - Canfield, Steven E.

AU - Dabestani, Saeed

AU - Giles, Rachel H.

AU - Hofmann, Fabian

AU - Hora, Milan

AU - Kuczyk, Markus A.

AU - Lam, Thomas

AU - Marconi, Lorenzo

AU - Merseburger, Axel S.

AU - Volpe, Alessandro

AU - Bex, Axel

N1 - Funding Information: Conflicts of interest: T. Powles is a company consultant for Novartis, Pfizer, GSK; has received company speaker honoraria from Novartis, Pfizer, GSK, Genentech; performed trial participation for GSK, Pfizer, BMS, Genentech, Genetech; and received grants/research support from GSK, Pfizer, and Novartis. A. Bex has received company speaker honoraria from Pfizer; performed trial participation for Pfizer Europe; participated on advisory boards for GSK and Novartis; is a company consultant for Pfizer and Novartis; and received grants/research support from Pfizer. M. Staehler is a company consultant for Pfizer, Novartis, GSK, Roche, Astellas, Bayer; has received company speaker honoraria from Pfizer, Novartis, GSK, Roche, Astellas, Bayer, Aveo; has performed trial participation for Pfizer, Novartis, GSK, Roche, Bayer, Aveo, Wilex, Immatics; has received fellowships and travel grants from Pfizer, Novartis, GSK, Roche, Bayer; has received grants/research support from Pfizer, Novartis, GSK, Roche, Bayer, and Aveo. B. Ljungberg has received company speaker honoraria from GlaxoSmithKline, Roche, Pfizer, Novartis; performed trial participation for GlaxoSmithKline, Medivation, Pfizer, Janssen R&D, Inc.; and been on advisory boards for Pfizer and GSK. K. Bensalah has received grants/research support from Pfizer and honoraria or consultation fees from Intuitive Surgical. S. Canfield has received company speaker honoraria from Amgen, Genomic Health, Algeta, and Bayer. M. Hora has received company speaker honoraria from Covidien, Olympus, Janssen, Astellas; performed trial participation for Janssen; and received grants/research support from Ipsen. M.A. Kuczyk is a stock shareholder of Bayer Healthcare, Astellas, Storz, Pfizer, Wyeth, Novartis; is a company consultant for Karl Storz, Coloplast, AstraZeneca, Astellas, Storz, Hexal AG; has received company speaker honoraria from Pfizer, Astellas, Bayer, GSK, Pierre Fabre, Janssen Cilag, Hexal; performed trial participation for the Protect Study, Millenium Study C21004, Millenium Study C21005, Astellas, Ipsen, Janssen; and received grants/research support from Wyeth and Pfizer. T. Lam is a company consultant for and has received company speaker honoraria from Pfizer, GSK, Astellas, and Ipsen. A. Merseburger is a company consultant for Ipsen Pharma, Bayer, Astellas, Janssen Cilag, Novartis, and Pfizer; has received company speaker honoraria from Ipsen Pharma, Wyeth, Astellas, Novartis, Pfizer, SEP; performed trial participation for AstraZeneca, Bayer, Pfizer, TEVA, Novartis, Astellas; received grants/research support from Wyeth; and participated in a company-sponsored speakers bureau for TEVA, Janssen, Pfizer, Astellas, Ferring, and Novartis. S. Dabestani, R.H. Giles, F. Hofmann, L. Marconi, and A. Volpe have nothing to disclose. Publisher Copyright: © 2016 European Association of Urology Copyright: Copyright 2017 Elsevier B.V., All rights reserved.

PY - 2016/11

Y1 - 2016/11

N2 - The European Association of Urology renal cancer guidelines panel recommends nivolumab and cabozantinib over the previous standard of care in patients who have failed one or more lines of vascular endothelial growth factor–targeted therapy. New data have recently become available showing a survival benefit for cabozantinib.

AB - The European Association of Urology renal cancer guidelines panel recommends nivolumab and cabozantinib over the previous standard of care in patients who have failed one or more lines of vascular endothelial growth factor–targeted therapy. New data have recently become available showing a survival benefit for cabozantinib.

UR - https://www.scopus.com/pages/publications/84977627563

U2 - 10.1016/j.eururo.2016.06.009

DO - 10.1016/j.eururo.2016.06.009

M3 - Journal articles

C2 - 27349614

AN - SCOPUS:84977627563

SN - 0302-2838

VL - 70

SP - 705

EP - 706

JO - European Urology

JF - European Urology

IS - 5

ER -

European Association of Urology Guidelines for Clear Cell Renal Cancers That Are Resistant to Vascular Endothelial Growth Factor Receptor–Targeted Therapy

Abstract

Funding

UN SDGs

Research Areas and Centers

Access to Document

Other files and links

Fingerprint

Cite this